SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a massive surge after delivering a blowout quarterly earnings report that significantly outpaced revenue and profit expectations, fueled by strong data center and AI demand. The community is actively debating the stock's sudden re-rating and massive valuation gap, with many investors celebrating a historic turnaround while others remain skeptical of the underlying fundamentals versus the hype.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are surging in sympathy with Intel's earnings beat, as investors rotate capital into semiconductor stocks amid a broader rally in the AI hardware sector. The community is sharply divided, with bulls celebrating an explosive momentum-driven melt-up, while bears caution that the recent parabolic move and rapid sentiment shift signals potential blow-off top conditions.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors react to the appointment of a new CEO for its Tanbreez project and the recent consolidation of majority ownership in the Greenland-based rare earth asset. Community discussion is heavily focused on the company's strategic position in the Western critical minerals supply chain, with many debating the impact of recent institutional capital raises and speculating on future price performance as the project moves toward operational development.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a surge in investor interest and extreme trading volume, fueled by confirmed purchase orders from Marvell and widespread speculation regarding its role in the AI data center supply chain. The community is actively discussing the companys transition from early-stage R&D to commercial manufacturing, with shareholders fiercely debating the valuation against the backdrop of an aggressive short squeeze.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz Inc. is experiencing significant volatility and trending across social media following a major legal victory where a federal jury awarded the company over $1 billion in damages and disgorgement against rival Papaya Gaming. The community is heavily focused on the potential for a massive short squeeze due to the stock's low float, institutional backing, and intense debate over whether the company can successfully collect the court-awarded funds.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is experiencing intense volatility as investors react to the news of cannabis rescheduling, with the community expressing frustration over aggressive sell-offs despite the potential long-term tax and banking benefits. While many traders remain focused on historical price levels and potential short squeezes, a significant portion of the community is voicing concerns over perceived market manipulation and dilution, leading to a deep divide between those holding for a long-term sector recovery and those skeptical of institutional motives.

ASGN Incorporated engages in the provision of information technology services and solutions. It operates through the Commercial and Federal Government segments. The Commercial segment involves the provision of consulting, creative digital marketing, and permanent placement services. The Federal Government segment provides mission-critical solutions. The company was founded on December 30, 1985 and is headquartered in Glen Allen, VA.

ASGN Inc

ASGN Inc. is trending as investors digest a significant price decline following disappointing quarterly earnings and guidance. Community sentiment is deeply polarized, with some traders viewing the pullback as a buying opportunity based on the company's valuation and pending rebrand to Everforth, while others are calling for regulatory investigations into alleged market manipulation and poor financial performance.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

Seeker ($SKR) is garnering significant community attention following its recent exchange listings and its role as the native token for the Solana Mobile smartphone ecosystem. Investors are actively discussing the token's utility in staking and governance, with many closely tracking volume patterns and potential price catalysts amid high volatility.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following the announcement of its acquisition of LivePerson, a move investors are evaluating as a strategic effort to consolidate voice and digital messaging capabilities into a unified omnichannel AI platform. While bullish community members highlight the immediate expansion of the enterprise customer base and cross-selling potential, the stock is seeing heightened volatility as traders weigh the integration risks and the impact of the deal on the company's valuation.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is surging amid high trading volume as investors react to strengthening technical signals and persistent buyout speculation surrounding the company's Briumvi commercial progress. The community remains focused on potential M&A activity and upcoming clinical readouts, with many traders discussing the stock's positioning against recent sector-wide deals and CEO Michael Weisss performance-based incentives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The authority said it has received 43 claims from patients who believe they developed the condition known as NAION after taking Wegovy or Ozempic.</li><li>Though the agency granted compensation in four claims, it also rejected one, bringing the total number of settled cases to five.</li><li>As per the agency, not all cases automatically qualify for compensation, but instead, each claim will be assessed individually.</li></ul><p>Four patients taking Novo Nordisk’s (NVO) weight loss drugs have been granted compensation in Denmark after they developed an adverse reaction that affected their eyes.</p><p>The four claimants will receive a combined 800,000 kroner, though that figure may rise, Danish Patient Compensation <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://patienterstatningen.dk/presse-og-nyheder/nyheder/2025/nov/de-foerste-patienter-faar-erstatning-for-alvorlig-oejensygdom-efter-wegovy-og-ozempic">said</a> on Friday. If it is proved that the eye disease is to blame for the patients not being able to do their jobs to the same extent as before, they will be entitled to compensation for loss of earning capacity, the authority said.</p><h2 class="st-heading-2">Cases In Question</h2><p>The authority said it has received 43 claims from patients who believe they developed the condition known as NAION after taking Wegovy or Ozempic.</p><p>NAION, or non-arteritic anterior ischemic optic neuropathy, is a medical condition causing sudden, painless vision loss due to a lack of blood flow to the optic nerve. There is no cure for the condition, which can cause blurry or worsening vision, reduced color vision, and optic disc swelling.</p><h2 class="st-heading-2">Compensation Not Guaranteed</h2><p>Though the agency granted compensation in four claims, it also rejected one, bringing the total number of settled cases to five. According to the agency, not all cases automatically qualify for compensation; each claim will be assessed individually to determine whether compensation is warranted.</p><p>“NAION is a serious disease that causes permanent and incurable damage to vision. It is also a very complex case to assess because it is a new medicine and the patients are already in the risk group for getting NAION. Our task is to give patients a thorough and well-thought-out decision," director of Patient Compensation, Karen-Inger Bast, said. &nbsp;</p><p>The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) considers NAION to be a rare side effect of Wegovy, Ozempic, and Rybelsus.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p><a href="https://stocktwits.com/symbol/NVO">NVO shares</a> traded 1% lower on Friday morning at the time of writing. On Stocktwits, retail sentiment around NVO stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.</p><p>NVO stock is down 45% this year and by about 54% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-etfs-hit-record-outflows-average-investor-now-in-the-red/cLPMoktREOm">Bitcoin ETFs Hit Record Monthly Outflows In November – Average Investor Now in the Red, Says Analyst</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic

The four claimants will receive a combined 800,000 kroner, though that figure may rise, Danish Patient Compensation said on Friday.

Equity

The four claimants will receive a combined 800,000 kroner, though that figure may rise, Danish Patient Compensation said on Friday.


<ul class="summary-bullets"><li>The facility is part of the company’s commitment, earlier this year, to invest $23 billion in the U.S. over the next five years.&nbsp;</li><li>Novartis is now also planning two additional RLT manufacturing facilities in Florida and Texas.&nbsp;</li><li>The U.S. is one of Novartis’ priority geographies in addition to China, Germany, and Japan.</li></ul><p>Novartis (NVS) on Monday said that it has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, marking its third RLT manufacturing site in the country.</p><p>The facility is part of the company’s commitment earlier this year to invest $23 billion in the U.S. over the next five years.</p><h2 class="st-heading-2">Goals Of The New Facility</h2><p>The new facility is designed to add capacity for radioligand therapy, meeting future demand, and enhance the company’s supply chain capabilities, Novartis <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-opens-new-radioligand-therapy-manufacturing-facility-california-part-23b-us-expansion-plan">stated.</a></p><p>Radioligand therapy is a targeted cancer treatment that combines a radioactive substance (radioisotope) with a cancer-targeting molecule (ligand). It is aimed at reducing damage to surrounding cells.</p><p>However, each RLT dose is custom-made and time-sensitive, making proximity to treatment centers and transit hubs necessary for patient access. The new site will ensure access to patients across the western U.S., Alaska, and Hawaii, Novartis said.</p><p>Commercial manufacturing at the facility is expected to begin once approval is granted by the U.S. Food and Drug Administration, the company added.</p><h2 class="st-heading-2">Future Expansion Plans</h2><p>Novartis is now also planning two additional RLT manufacturing facilities in Florida and Texas. &nbsp;</p><p>In addition, it is also eyeing expansion of existing sites in Durham, North Carolina, Indianapolis, Indiana, and Millburn, New Jersey, and expects to establish a second global research and development hub in the U.S. in San Diego, California.</p><p>The U.S. is one of Novartis’ priority geographies, alongside China, Germany, and Japan.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">NVS stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.</p><p>NVS stock is up 31% this year and approximately 20% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/grab-holdings-to-take-equity-interest-in-remote-driving-tech-startup/cLPcKrSRE2c">Grab Deepens Autonomous Mobility Push With $60 Million Investment In Vay</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Opens New Manufacturing Facility In California In Bid To Increase US Presence

Commercial manufacturing at the facility is expected to begin once approval is granted by the U.S. Food and Drug Administration, the company added.

Current Price	$25.82
Prev Close	$26.15
Open	$25.90
Dividend Yield	N/A
50-Day Moving Average	$26.23
Beta	N/A
Avg. Volume	45,279.83
PE Ratio	N/A

52-Week High	$28.15
52-Week Low	$24.10
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

QLTI
QLT Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest QLTI News

QLTIQLT Inc.